Jeremy Batstone-Carr, director of private client research at stockbroker Charles Stanley, reveals his picks for 2011
AstraZeneca A bold call for 2011 undoubtedly. Not only are pharmaceutical stocks likely to be more in vogue in 2012, but if equity markets blaze higher over 2011 the shares may lag. Operationally, investors are already well aware of the company’s looming off-patent cliff, but trading off just 7.5 times estimated 2011 offering an estimated free cashflow yield of 13.5%, the risk of ownership is significantly offset by the tangible rewards. Autonomy Corporation While performance on cash generation and the reaction to a significant acquisition may drive the shares (up or down) in the fi...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
